Our June 2023 Quick Question asked, “Name the bispecific antibody-based FVIII inhibitor bypass agent.” Our 68 respondents answered…
- Caplacizumab [Cablivi]: 3 [4%]
- Eculizumab [Soliris]: 8 [12%]
- Emicizumab [Hemlibra]: 53 [78%]
- Eloctate: 3 [4%]
- Jivi: 1 [2%]
Genentech’s emicizumab is the bispecific antibody that bypassed FVIII in to join FIX to FX, activating FX. Emicizumab is available to all hemophilia A sufferers including those with anti-VIII inhibitors.
Caplacizumab is Sanofi’s VWF-specific nanobody designed to treat TTP by suppressing the activity of ULWF. Caplacizumab is the first nanobody-based therapeutic.
Eculizumab is Alexion’s complement factor V antibody first designed to treat paroxysmal nocturnal hemoglobinuria [PNH] and is now approved to treat atypical hemolytic-uremic syndrome [aHUS}.
Eloctate [Sanofi] and Jivi [Bayer] are two examples of the several extended half-life FVIII concentrates available since 2014 that are routinely used for hemophilia A prophylaxis.
Not listed in the question is Novo Nordisk’s concizumab, an anti-TFPI antibody therapeutic currently under FDA review that may become available to treat hemophilia A and B.
No comments here.